omniture
Ascletis BioScience Co.,Ltd./歌礼生物科技(杭州)有限公司

Latest News

Ascletis' All-oral HCV Treatment Approved for Marketing in China

HANGZHOU and SHAOXING, China, July 31, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2020-07-31 08:47 7528

Bridging Study in China Completed for NASH Drug Candidate ASC40

HANGZHOU and SHAOXING, China, July 20, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2020-07-20 08:30 3095

ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial

HANGZHOU, China and SHAOXING, China, June 17, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code:...

2020-06-17 20:30 1803

Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication

HANGZHOU, China and SHAOXING, China, May 13, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: ...

2020-05-13 18:30 1600

Ascletis Receives IND Approval for its HIV Drug ASC09F

HANGZHOU and SHAOXING, China, April 13, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672)...

2020-04-13 20:00 1600

Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020

HANGZHOU and SHAOXING, China, April 1, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2020-04-01 08:30 1506

Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients

HANGZHOU and SHAOXING, China, March 25, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672)...

2020-03-25 08:28 1540

Progress of the Small Sample Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia

HANGZHOU, China and SHAOXING, China, March 10, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code...

2020-03-10 17:30 1643

Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia

HANGZHOU and SHAOXING, China, Feb. 27, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2020-02-27 08:00 2135

Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA

HANGZHOU, China and SHAOXING, China, Feb. 18, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code:...

2020-02-18 08:00 1520

Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody

HANGZHOU and SHAOXING, China, Jan. 23, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK...

2020-01-23 09:52 1658

Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout

HANGZHOU, China and SHAOXING, China, Nov. 29, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), ...

2019-11-29 08:00 1130

Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer

HANGZHOU, China and SHAOXING, China, Oct. 8, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), a...

2019-10-08 08:00 853

Ascletis Announces Departure of Chief Financial Officer

HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an inn...

2019-09-30 16:30 424

Ascletis Announces Departure of Chief Financial Officer

HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an inn...

2019-09-30 16:30 734

Ascletis Received IND Approval for its NASH Drug

HANGZHOU, China and SHAOXING, China, Aug. 28, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), ...

2019-08-28 08:00 2032

Ascletis Opens Clinical Development Shanghai Center

HANGZHOU and SHAOXING, China, Aug. 12, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an inno...

2019-08-12 18:00 1099

Ascletis Received IND Approval and Management Outlook of 2019 and Beyond

HANGZHOU and SHAOXING, China, Aug. 5, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innov...

2019-08-05 08:00 1972

3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH

SAN MATEO, Calif. and HANGZHOU and SHAOXING, China, May 1, 2019 /PRNewswire/ -- 3-V Biosciences, In...

2019-05-01 06:00 5333

Ganovo is Eligible for the Basic Medical Insurance of Zhejiang Province - Reimbursement-by-disease

HANGZHOU and SHAOXING, China, April 15, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.H...

2019-04-15 17:12 3066
12